What is NDC 61755-018?

61755-018 is the product NDC for Inmazeb, Atoltivimab 241.7 mg/14.5mL + 2 more ingredients injection, solution, listed with the FDA by Regeneron Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Inmazeb (Atoltivimab, maftivimab, and odesivimab-ebgn).

What is the active ingredient?

Atoltivimab, Maftivimab, Odesivimab.

Regeneron Pharmaceuticals, Inc., NDC labeler code 61755. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Inmazeb?

1 other product NDC are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Inmazeb NDC 61755-018 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)61755-018Labeler and product segments. Claims need a package NDC.

Product NDC at billing width61755-0018Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
61755-018-01	61755001801	1 VIAL, SINGLE-DOSE in 1 CARTON (61755-018-01) / 14.5 mL in 1 VIAL, SINGLE-DOSE (61755-018-00)Marketed from Oct 14, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Inmazeb
Generic name (nonproprietary): atoltivimab, maftivimab, and odesivimab-ebgn
Active ingredients: Atoltivimab — 241.7 mg/14.5mLMaftivimab — 241.7 mg/14.5mLOdesivimab — 241.7 mg/14.5mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Regeneron Pharmaceuticals, Inc.NDC labeler code 61755
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761169
Marketing start: Oct 14, 2020
Listing expires: Dec 31, 2026
Identifiers: Product ID 61755-018_03d5650a-82d9-4af5-9515-ea52c93733efSPL ID 03d5650a-82d9-4af5-9515-ea52c93733efSPL set ID 0536b6fe-6fe5-4fd6-8cc6-1b481945c1faRxCUI 2461536, 2461539, 2571682, 2571685UNII FJZ07Q63VY, KOP95331M4, UY9LQ8P6HW

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N461755001801 followed by a unit qualifier and the quantity

Package 61755-0018-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 15, 2025.

Indications (excerpt from the label)

INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection [see Dosage and Administration (2.2) , and Clinical Studies (14) ] . INMAZEB is a combination of Orthoebolavirus zairense glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection. ( 1 ) Limitation of Use The efficacy of INMAZEB has not bee…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 61755-018

What is NDC 61755-018?: 61755-018 is the product NDC for Inmazeb, Atoltivimab 241.7 mg/14.5mL + 2 more ingredients injection, solution, listed with the FDA by Regeneron Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Inmazeb (Atoltivimab, maftivimab, and odesivimab-ebgn).
What is the active ingredient?: Atoltivimab, Maftivimab, Odesivimab.
Who is the labeler?: Regeneron Pharmaceuticals, Inc., NDC labeler code 61755. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Inmazeb?: 1 other product NDC are listed under this name. See all Inmazeb NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Inmazeb NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Inmazebatoltivimab, maftivimab, and odesivimab-ebgn	Atoltivimab 483.3 mg/14.5mL + 2 more ingredients	Injection, SolutionIntravenous	Regeneron Pharmaceuticals, Inc.	61755-019	61755-0019-01

Other NDCs under BLA 761169

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761169
Product	Strength	Form · route	Labeler	Product NDC
Inmazebatoltivimab, maftivimab, and odesivimab-ebgn	Atoltivimab 483.3 mg/14.5mL + 2 more ingredients	Injection, SolutionIntravenous	Regeneron Pharmaceuticals, Inc.	61755-019